Eminence Business Media - A Eminence Group Company’s Post

Excited to attend the Why Summits Pharma and Biotech Project, Program and Portfolio Management Conference this year! At Atlas, we specialize in driving operational excellence by helping life sciences companies optimize their portfolios, streamline execution, and achieve measurable impact. Can’t wait to engage with peers and share how we empower transformative change through Project, Program, and Portfolio Management. Together, we’re shaping the future of PPM! #WhyPPM #OperationalExcellence #LifeSciences #AtlasImpact Let me know if you'll be there!

3 DAYS LEFT: Redefining Pharma Portfolio Value Analytics From spreadsheets to dynamic insights: The future is here. Discover how advanced portfolio analytics is transforming strategic portfolio decision making for the life sciences organizations.   Who Should Attend: - Portfolio leaders - R&D heads - Strategic decision-makers - Project managers - Biotech pipeline managers Register now and get a chance to interact with our PPM experts and discuss trends and best practices. For registration, click here: https://lnkd.in/dEzrwXfE #i2econsulting #PPM #PortfolioAnalytics #LifeSciences #Webinar #StrategicPlanning #UpcomingWebinar

The New Product Planning summit was packed with valuable insights. One standout theme was the introduction of PCS (Probability of Commercial Success) in addition to the traditional PTRS framework to emphasize the importance of early commercial considerations. Here are 7 key themes that resonated with me: 1. Align Goals and Incentives Across the Enterprise – Ensure cross-functional alignment by setting clear, shared objectives from the early stages. Everyone should be on the same page with the strategic direction to drive the asset forward. If you see misalignment, lean into it, speak up early, and openly address the challenge. 2. Consider Future Impact of the IRA in Pipeline Planning – The IRA introduced additional pricing, access, and fulfillment considerations. Near-launch market access planning is no longer adequate—consider the IRA implications and trends as part of drug candidate selection and new product planning strategy to maximize the lifetime value of pipeline assets. 3. Manage Capital and Risk Effectively – In a constrained capital environment, every decision matters even more. De-risk development by being thoughtful about indication prioritization, sequencing, and lifecycle management while remaining agile and adaptable to changes in the market. 4. Clarify Strategic Trade-offs – Managing trade-offs is central to NPP success. Clarifying assumptions and constraints and balancing time, costs, risks, and the commercial potential of an asset improves decision-making. 5. Engage Early and Broadly with Stakeholders – Engage with internal and external stakeholders (health authorities, regulatory bodies, payers, and KOLs) early. Get feedback on endpoints that matter for both clinical relevance and reimbursement strategy to get it right: "We can't afford to make mistakes." 6. Think Beyond the First Launch – Successful lifecycle management requires early planning for indication prioritization and sequencing. Especially in an evolving market shaped by the IRA and increased competitive pressures, timing strategies and discipline around strategic value creation are ever more critical. 7. Be Curious, Humble, and Collaborative – Drug development is a team sport. Build bridges and relationships across functions. Curiosity and humility open doors to collaboration. Thank you to the presenters and facilitators for sharing valuable perspectives. #NewProductPlanning #NPPSummit

What’s the secret to seamless stakeholder alignment in pharma projects? Join Jayesh Khatri at the 8th Annual Pharma Project and Portfolio Management 2025 as he delves into mastering communication and soft skills. Learn to align stakeholders, address conflicts early, and leverage tools to keep your pharma projects on track for success! Register Now: https://lnkd.in/dy3TCGeh #ebmpppm2025 #eminencegroupventures #eminencebusinessmedia #portfolio #projectmanagement

The Portfolio Track on Day 3 began with an inspiring case study by Tanya Kranenburg, PhD, PMP, Director of Research Portfolio Management at Regeneron. 🌟✨ Tanya shared the transformative journey of implementing a streamlined Project Portfolio Management (PPM) system in biotech discovery. From user-centric design and real-time data access to enhanced efficiency and adaptability, attendees gained actionable insights into fostering transparency and driving innovation in their organizations. 🚀📊 #PortfolioManagement #InnovationInBiotech #Portfolio2024 #LeadershipInProjects #PPMExcellence

We initiated a Phase I study in just 3.5 weeks—70% faster than the industry's standard 12-week timeline! The key? Effective communication, strategic planning, and breaking down silos. We aligned our internal team, maintained an open dialogue with the sponsor, and optimized project management with two leads in different time zones for quicker decision-making. This isn't just another success story—it's your roadmap to faster drug development. #ClinicalTrials #DrugDevelopment #ProjectManagement

I am attending the 8th Annual Pharma Project and Portfolio Management 2025. Keep learning, keep growing. Eminence Business Media - A Eminence Group Company #ebmpppm2025 #eminencegroupventures #eminencebusinessmedia #pharmaportfolio

Looking forward to all the questions from the experts at phraktion following this presentation! #phraktion #projectmanagement #riskmanagement

And while I am not at JPM this year for only the second time in some 20 years, please don't hesitate to reach out if you have evolving questions in Oncology around your platform, programs or indications. Our expertise in Oncology is unparalleled across MOAs, therapeutic modalities, tumor types, and needs specific to the various stages of development from pure platform to preclinical and pre-POC to moving towards late stage registrational trials and potential launch. We were at the forefront of IO back in the early 2000s, as well as precision medicine, and the expanding role of diverse biologics. Reach out now to see how our strategic Oncology experience over many years can help you work through key questions you may be facing now or anticipate facing over the coming year. #cancer #oncology #immunotherapy #immunooncology

Prioritisation is something many Pharma leaders struggle with. It’s tough. Especially if: A) Your “value” criteria aren’t clear. B) Your teams are stuck in silos. Here are the 4 most critical aspects of prioritisation to master: 1 - 𝐊𝐧𝐨𝐰 𝐲𝐨𝐮𝐫 𝐭𝐨𝐩 𝐩𝐫𝐢𝐨𝐫𝐢𝐭𝐢𝐞𝐬—𝐚𝐧𝐝 𝐰𝐡𝐲 𝐭𝐡𝐞𝐲’𝐫𝐞 𝐭𝐨𝐩. Don’t waste time perfecting models if the same top items keep surfacing. Focus on those that truly matter. 2 - 𝐂𝐨-𝐜𝐫𝐞𝐚𝐭𝐞 𝐢𝐧𝐩𝐮𝐭𝐬 𝐭𝐨 𝐛𝐮𝐢𝐥𝐝 𝐚𝐥𝐢𝐠𝐧𝐦𝐞𝐧𝐭. Every stakeholder should understand—and ideally agree—on the top priorities, even if it’s not their favourite project. 3 - 𝐊𝐞𝐞𝐩 𝐭𝐡𝐞 𝐥𝐢𝐬𝐭 𝐥𝐞𝐚𝐧. I’ve seen teams asked to prioritise a list of 20 items. Cut it down to under 10. Group related tasks or themes if you need to. 4 - 𝐄𝐦𝐛𝐫𝐚𝐜𝐞 𝐢𝐦𝐩𝐞𝐫𝐟𝐞𝐜𝐭𝐢𝐨𝐧. No process is perfect, and that’s okay. A framework is a great guide and starting point for discussions. If you need to deviate—and everyone’s on board—it’s not a failure. When it comes to Pharma Projects, I like the Patient-Centric Value Framework: Patient Impact, Clinical Value, Market Potential, Regulatory Feasibility, Resource Allocation. 𝐖𝐡𝐚𝐭 𝐰𝐨𝐫𝐤𝐬 𝐟𝐨𝐫 𝐲𝐨𝐮? #pharmaprioritisation #patientcentric #pharmaleadership #clinicalvalue #pharmastrategy #marketpotential #regulatoryaffairs